Sign in to fuzzto save your conversations, follow your research and come back anytime.
Sanjivani Paranteral
SANJIVIN
BSE
BSESectorHealthcare
190.00
Loading chart…
BSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Export-led revenue growth and strong margins drive profitability, though rising costs and a shrinking nutraceutical segment require attention.
Revenue grew from ₹179 Cr in Q1 FY26 to ₹238.39 Cr in Q1 FY27 — driven by strong overseas demand
Nutraceuticals revenue collapsed from ₹12.1 Cr in Q2 FY26 to ₹0.18 Cr in Q1 FY27 — signaling a major segment slowdown
Export share expanded from 73.7% in Q1 FY26 to 90.50% in Q1 FY27 — making international markets the core growth engine
Employee costs climbed from ₹14.9 Cr in Q2 FY26 to ₹23.54 Cr in Q1 FY27 — reflecting aggressive hiring for expansion
EBITDA margin improved from 15.0% in Q1 FY26 to 18.01% in Q1 FY27 — showing better cost control and pricing power
Finance costs increased from ₹0.5 Cr in Q2 FY26 to ₹3.47 Cr in Q1 FY27 — adding pressure from higher debt servicing
Injectables revenue rose from ₹89.9 Cr in Q1 FY26 to ₹110.12 Cr in Q1 FY27 — maintaining its position as the top revenue driver
Depreciation jumped from ₹1.6 Cr in Q1 FY26 to ₹6.52 Cr in Q1 FY27 — indicating heavy capital investments being amortized
Profit after tax recovered from ₹16.4 Cr in Q2 FY26 to ₹24.91 Cr in Q1 FY27 — confirming steady bottom-line delivery
Other expenses rose from ₹14.2 Cr in Q2 FY26 to ₹23.92 Cr in Q1 FY27 — pointing to rising operational overheads
